Mar 08, 2022 04:23 AM

BUSINESS

China Meheco Confirms Pfizer Talks on Selling Paxlovid in China

By Cui Xiaotian and Denise Jia

Pfizer’s Covid-19 pill Paxlovid lowered hospitalization and death rates by 89% in patients who took it within five days of the onset of illness.

Pfizer’s Covid-19 pill Paxlovid lowered hospitalization and death rates by 89% in patients who took it within five days of the onset of illness.

China Meheco Corp. (600056.SH) is in talks on commercializing Pfizer’s new Covid-19 pill in China, but the discussions are still at an early stage, the state-owned pharmaceutical company said Monday.

Boosted by speculation that China Meheco might become Pfizer’s partner for marketing Paxlovid in China, the company’s Shanghai-traded shares surged by the daily limit of 10% during four consecutive sessions since last Wednesday.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Asia New Vision Forum Kicks Off in Singapore

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin Deep Dive: Former Securities Regulator Yi Huiman’s Corruption Probe

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: Why Modi Won’t Play Cowboys and Indians With Trump, Opting Instead for Strategic Autonomy

2: Chinese Ex-Employee of U.S. Hedge Fund Two Sigma Faces Fraud Charges

3: Intel Names New China Chief Amid Business Transition and Market Shifts

4: China Doubles Down on Policy Drive to Boost Service Spending

5: XPeng Partners With Magna to Build EVs in Europe

SPONSORED

OR